TABLE 2.
Percentage of paediatrics predicted to achieve target infliximab trough concentrations by dosing regimen
| Percentage (%) achieved target Ctrough |
||||
|---|---|---|---|---|
| > 3 ug/mL | > 5 ug/mL | > 7 ug/mL | > 16 ug/mL | |
| 5 mg/kg | ||||
| Q8W | 73.7 | 50.8 | 30.1 | 2.80 |
| Q6W | 94.1 | 82.8 | 66.3 | 16.7 |
| Q4W | 99.8 | 98.7 | 95.9 | 60.1 |
| 7.5 mg/kg | ||||
| Q8W | 87.2 | 68.7 | 53.9 | 13.5 |
| Q6W | 97.9 | 92.6 | 85.0 | 38.9 |
| Q4W | 100 | 99.6 | 98.7 | 85.0 |
| 10 mg/kg | ||||
| Q8W | 91.9 | 80.8 | 66.7 | 23.0 |
| Q6W | 98.8 | 96.7 | 91.3 | 58.1 |
| Q4W | 100 | 99.8 | 99.6 | 93.3 |
| 12.5 mg/kg | ||||
| Q8W | 94.4 | 87.0 | 76.0 | 34.6 |
| Q6W | 99.4 | 97.9 | 95.4 | 70.2 |
| Q4W | 100 | 100 | 99.8 | 96.7 |
| 15 mg/kg | ||||
| Q8W | 96.6 | 89.4 | 82.9 | 46.4 |
| Q6W | 99.6 | 98.7 | 97.0 | 79.5 |
| Q4W | 100 | 100 | 99.8 | 98.0 |
Percentages were calculated based on the results of 1000 simulations in 10-year-old male populations accounting for inter-individual variability and without residual error.